Aligos Therapeutics (ALGS) Change in Account Payables (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Change in Account Payables came in at $3.7 million in Q1 2026, up 111.39% YoY from $1.7 million in Q1 2025, and up 646.64% on a QoQ basis from -$669000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Change in Account Payables (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Change in Account Payables data on file, last reported at $3.7 million in Q1 2026.
- Quarterly Change in Account Payables rose 111.39% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 128.79% YoY) and the FY2025 annual result came in at $1.4 million, up 2512.96% from the prior year.
- Change in Account Payables advanced to $3.7 million in Q1 2026, from -$669000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $4.0 million in Q2 2024 to a low of -$4.1 million in Q3 2024.
- A 5-year average of $272058.8 and a median of $169000.0 in 2022 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 849.16% in 2024, down 1259.67% in 2024.
- Tracing ALGS's Change in Account Payables over 5 years: stood at $1.8 million in 2022, then tumbled by 123.42% to -$423000.0 in 2023, then jumped by 60.05% to -$169000.0 in 2024, then slumped by 295.86% to -$669000.0 in 2025, then soared by 646.64% to $3.7 million in 2026.
- The last three Change in Account Payables figures came in at $3.7 million (Q1 2026), -$669000.0 (Q4 2025), and $752000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | -1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.21 Mn |
| Jun 30, 2026 | -1.21 Mn |
| Mar 31, 2026 | 3.66 Mn |
| Mar 31, 2026 | 3.66 Mn |
| Dec 31, 2025 | -669,000.00 |
| Dec 31, 2025 | -669,000.00 |
| Sep 30, 2025 | 752,000.00 |
| Sep 30, 2025 | 752,000.00 |
| Jun 30, 2025 | -402,000.00 |
| Jun 30, 2025 | -402,000.00 |
| Mar 31, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | -169,000.00 |
| Dec 31, 2024 | -169,000.00 |
| Sep 30, 2024 | -4.08 Mn |
| Sep 30, 2024 | -4.08 Mn |
| Jun 30, 2024 | 3.98 Mn |
| Jun 30, 2024 | 3.98 Mn |
| Mar 31, 2024 | 325,000.00 |
| Mar 31, 2024 | 325,000.00 |